BlueWillow Biologics Names Leading Viral Infectious Disease Experts to Scientific Advisory Board

×

Error message

  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ds_changed in eval() (line 16 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$ss_search_api_url in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).
  • Notice: Undefined property: stdClass::$tm_title in eval() (line 20 of /var/www/7/modules/php/php.module(80) : eval()'d code).

BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.

Metadata
Provider: 
Business Wire, Inc.Business Wire, Inc.
Retrieved on: 
Tuesday, September 21, 2021
Information
Tags: 
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Infectious Diseases, Clinical Trials, Novartis Institute for Tropical Diseases, Therapy, Infection, Vertically transmitted infection, Developmental Biology (journal), Vaccine, SAB, Howard Hughes Medical Institute, Merck & Co., National, University, Coronavirus Scientific Advisory Board (Turkey), Wyeth, Virus, Senior, Immunology, Merck, Company, LLC, Columbia University, Biological Technologies Office (DARPA), COVID-19, Research, Anthrax, RSV, Degenerative disease, International Medical Education Directory, Food, Massachusetts Institute of Technology, Waldemar von Zedtwitz, Urinary tract infection, Biomedical Research, HSV, MedImmune, Massachusetts, Department, Pharmaceutical industry
Geotags: 
Michigan, United States, TORONTO, AUCKLAND
⚠ generated by AI ↴
Organisation: 
BLUEWILLOW BIOLOGICS
Summary
Key Points: 
  • BlueWillow Biologics, Inc. , a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts.
  • The members of the BlueWillow Biologics SAB include:
    Robin Isaacs, M.D.
  • Prior, he held positions of increasing responsibility at Merck & Co., Inc., most recently serving as Vice President and Therapeutic Area Head, Vaccine Clinical Research.
  • We are proud to have such a distinguished team of scientific experts serve as members of our Scientific Advisory Board, underscoring their belief in our intranasal vaccines to elicit mucosal immunity, commented Chad Costley, M.D., President and Chief Executive Officer of BlueWillow Biologics.


BlueWillow Biologics, Inc., a privately held clinical-stage biopharmaceutical company developing intranasal vaccines, today announced the formation of the Company's Scientific Advisory Board (SAB) with three leading viral infectious disease experts. The SAB will provide strategic and scientific counsel to BlueWillow’s clinical programs.

The members of the BlueWillow Biologics SAB include:

  • Robin Isaacs, M.D. – Dr. Isaacs was Chief Medical Officer of Entasis Therapeutics for 4 years. Prior, he held positions of increasing responsibility at Merck & Co., Inc., most recently serving as Vice President and Therapeutic Area Head, Vaccine Clinical Research. During his 18 years at Merck, Dr. Isaacs was involved with the worldwide development, regulatory submission and approval of several anti-infective, antiviral and vaccine products. He holds an M.B., B.H.B and M.D. from the University of Auckland.
  • Akiko Iwasaki, Ph.D. – Dr. Iwasaki is a Waldemar Von Zedtwitz Professor at the Yale University Department of Immunobiology and Department of Molecular Cellular and Developmental Biology. She is currently an Investigator at the Howard Hughes Medical Institute. Dr. Iwasaki’s research focuses on the mechanisms of immune defense against viruses on mucosal surfaces, and her laboratory explores the relationship between viral infections and adaptive immunity. She holds a B.S. and Ph.D. from the University of Toronto. Dr. Iwasaki completed her Postdoctoral Fellowship at the National Institutes of Health Intramural Research Program.
  • Steve Projan, Ph.D. – Dr. Projan is a Principal at Beat the Reaper, LLC. Previously, he served as a Senior Vice President of R&D in the Infectious Diseases & Vaccines Innovative Medicines unit (iMED) at MedImmune, where he led the strategy, prioritization and advancement of the company’s infectious disease and vaccine portfolio. Prior to MedImmune, Dr. Projan served as Vice President and Global Head of Infectious Diseases at the Novartis Institutes for Biomedical Research. He previously spent 15 years at Wyeth in roles of increasing responsibility, most recently as Vice President of Biological Technologies. He holds a B.S. from the Massachusetts Institute of Technology, as well as an M.A. and Ph.D. from Columbia University.

“We are proud to have such a distinguished team of scientific experts serve as members of our Scientific Advisory Board, underscoring their belief in our intranasal vaccines to elicit mucosal immunity,” commented Chad Costley, M.D., President and Chief Executive Officer of BlueWillow Biologics. “Their diverse expertise and experience in the field of infectious diseases will be integral as our team advances our research and clinical programs.”

About BlueWillow Biologics

BlueWillow Biologics is developing and enabling a new generation of safe and effective nasal vaccines to protect global populations from respiratory infections, sexually transmitted diseases and food allergies. Our novel intranasal adjuvant platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including COVID-19, pandemic flu, RSV, HSV, anthrax and peanut allergy. www.bluewillow.com

Copyright: 
Copyright Business Wire 2021